Display Settings:

Format

Send to:

Choose Destination
J Thorac Cardiovasc Surg. 2014 Apr;147(4):1362-7. doi: 10.1016/j.jtcvs.2013.09.048. Epub 2013 Nov 16.

The significance of natriuretic peptide in treatment of pulmonary hypertension after mitral valve replacement.

Author information

  • 1Chest Clinical Research Center, Tianjin Medical University, Tianjin, China.
  • 2Division of Cardiac Surgery, Tianjin Chest Hospital, Tianjin, China.
  • 3Division of Cardiac Surgery, Tianjin Chest Hospital, Tianjin, China. Electronic address: woolla@eyou.com.

Abstract

OBJECTIVES:

To compare the therapeutic efficacy of recombinant human brain natriuretic peptide and prostaglandin E1 in the treatment of pulmonary hypertension after mitral valve replacement.

METHODS:

Sixty patients with postoperative pulmonary hypertension were divided randomly into 3 groups that received saline, prostaglandin E1, and natriuretic peptide infusions for 12 hours each. The hemodynamics data were monitored consecutively, and the levels of thromboxane A2 and cyclic guanosine monophosphate were detected pretreatment, after treatment, and 1 week after surgery.

RESULTS:

The arterial pressure, pulmonary arterial pressure, and pulmonary capillary wedge pressure decreased 1 hour after prostaglandin E1 treatment and rebounded after treatment discontinuation. The pulmonary arterial pressure and pulmonary capillary wedge pressure in the natriuretic peptide group decreased 3 hours after treatment; pulmonary arterial pressure decreased less than that of the prostaglandin group, and there was no evidence of hemodynamic rebound after treatment discontinuation. The natriuretic peptide had no significant effects on arterial pressure. In both the prostaglandin and natriuretic peptide groups, cyclic guanosine monophosphate increased after the treatment, which was even higher in the latter group. Prostaglandin E1 could lead to the decrease of thromboxane A2, which was not seen in the natriuretic peptide group.

CONCLUSIONS:

Both brain natriuretic peptide and prostaglandin E1 can effectively reduce pulmonary hypertension; however, natriuretic peptide has a slower and milder efficacy. The effects of these 2 drugs in reducing the pulmonary arterial pressure may be mediated through different pathways.

Copyright © 2014 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

PMID:
24252943
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk